Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/15/2017 08/16/2017 08/17/2017 08/18/2017 08/21/2017 Date
26.91(c) 26.78(c) 26.88(c) 26.33(c) 26.37(c) Last
2 536 754 3 127 283 3 070 527 2 497 407 1 893 822 Volume
+0.64% -0.48% +0.37% -2.05% +0.15% Change
More quotes
Financials ($)
Sales 2017 395 M
EBIT 2017 90,9 M
Net income 2017 73,7 M
Finance 2017 230 M
Yield 2017 -
Sales 2018 568 M
EBIT 2018 193 M
Net income 2018 188 M
Finance 2018 396 M
Yield 2018 -
P/E ratio 2017 113,00
P/E ratio 2018 44,03
EV / Sales2017 19,0x
EV / Sales2018 12,9x
Capitalization 7 739 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company.It engages in the developing and commercializing small molecule therapies for the treatment of cancer.The company brands include comertriq and cobimetinib.Its pipeline consists of cabozantinib, cobimetinib and Xl 888. Exelixis was founded by Corey S.... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
08/18 EXELIXIS, INC. : Corporate News Blog - Exelixis Submits US Supplemental New Drug..
08/17 EXELIXIS : Submits U.S. Supplemental New Drug Application for CABOMETYX for the ..
08/16 EXELIXIS, INC. : Today's Research Reports on Trending Tickers: Exelixis Inc. and..
08/16 EXELIXIS : Submits U.S. Supplemental New Drug Application for CABOMETYX® (caboza..
08/10 EXELIXIS : Patent Issued for Processes for Preparing Quinoline Compounds and Pha..
08/03 EXELIXIS : tops Street 2Q forecasts
08/02 EXELIXIS : Management's Discussion and Analysis of Financial Condition and Resul..
08/02 EXELIXIS, INC. : Results of Operations and Financial Condition (form 8-K)
08/02 EXELIXIS, INC. (NASDAQ : EXEL) Files An 8-K Results of Operations and Financial ..
08/02 EXELIXIS : Announces Second Quarter 2017 Financial Results and Provides Corporat..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on EXELIXIS, INC. 
2013A downturn could form
More Strategies
Latest Tweets
08/18Biotech Forum Daily Digest: What's Next For Adamas Pharmaceuticals?  
08/18Biotech Forum Daily Digest: What's Next For Adamas Pharmaceuticals?  
08/18Wetherby Asset Management Inc. Takes Position in Exelixis, Inc. $EXEL  
08/17Exelixis: Time To Reach The Top  
08/17Alps Advisors Inc. Acquires 37,351 Shares of Exelixis, Inc. $EXEL  
More tweets
Qtime:59
News from SeekingAlpha
08/18 BIOTECH FORUM DAILY DIGEST : What's Next For Adamas Pharmaceuticals?
08/17 EXELIXIS : Time To Reach The Top
08/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 17, 2017
08/16 Opdivo's Renal Failure Boosts Exelixis - Or Does It?
08/16 BIOTECH FORUM DAILY DIGEST : Revisiting Bellicum Pharmaceuticals
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | 4-Traders
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 29,8 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Executive VP, Chief Financial & Accounting Officer
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.76.59%7 739
AMGEN14.42%122 067
CELGENE CORPORATION10.28%99 867
GILEAD SCIENCES0.70%94 170
REGENERON PHARMACEUTICALS26.41%50 145
VERTEX PHARMACEUTICALS101.07%37 346